We are live on
!
Find out more
VIA
Virtus Investment Advisers Portfolio holdings
AUM
$363M
1-Year Est. Return
34.89%
This Fund
S&P 500
This Quarter
Est. Return
+9.26%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$72M
(-20%)
Cap. Flow
-$84.2M
Cap. Flow
% of AUM
-28.48%
Top 10 Holdings %
Top 10 Hldgs %
6.88%
Holding
509
New
39
Increased
197
Reduced
202
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Constellation Energy
CEG
|
+$1.64M |
| 2 |
Veeva Systems
VEEV
|
+$1.51M |
| 3 |
Cisco
CSCO
|
+$1.5M |
| 4 |
Fox Class A
FOXA
|
+$1.48M |
| 5 |
DoorDash
DASH
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
+$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
+$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
+$19M |
| 4 |
SMC
Summit Midstream
SMC
|
+$3.67M |
| 5 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$2.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.24% |
| 2 | Healthcare | 17.43% |
| 3 | Technology | 12.41% |
| 4 | Industrials | 9.1% |
| 5 | Consumer Discretionary | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Stoke Therapeutics
STOK
$2.11B
| $90.3K | 0.03% |
7,955
-5,368
| -40% | -$51K |
|
377
Zymeworks
ZYME
$1.67B
| $90.1K | 0.03% |
7,178
-5,828
| -45% | -$69.4K |
|
|
ATXS
378
DELISTED
Astria Therapeutics
ATXS
| $90K | 0.03% |
16,792
+57
| +0.3% | +$276 |
|
379
Xenon Pharmaceuticals
XENE
$6.12B
| $89.7K | 0.03% |
2,867
-1,294
| -31% | -$42.2K |
|
380
Nurix Therapeutics
NRIX
$2.65B
| $89.5K | 0.03% |
7,862
-124
| -2% | -$1.34K |
|
381
GH Research
GHRS
$2.08B
| $89.3K | 0.03% |
+7,329
| New | +$80.3K |
|
382
Immunome
IMNM
$2.83B
| $89.3K | 0.03% |
9,605
-2,956
| -24% | -$24.2K |
|
|
MRUS
383
DELISTED
Merus
MRUS
| $89.3K | 0.03% |
1,698
-2,269
| -57% | -$107K |
|
|
UPB
384
Upstream Bio Inc
UPB
$395M
| $89.3K | 0.03% |
+8,134
| New | +$75.1K |
|
|
TERN
385
DELISTED
Terns Pharmaceuticals
TERN
| $89.2K | 0.03% |
23,927
-986
| -4% | -$3.08K |
|
386
AnaptysBio
ANAB
$1.68B
| $89.2K | 0.03% |
4,017
-6,909
| -63% | -$145K |
|
387
Vaxcyte
PCVX
$8.64B
| $88.7K | 0.03% |
2,729
+857
| +46% | +$28.1K |
|
388
Corvus Pharmaceuticals
CRVS
$1.17B
| $88.7K | 0.03% |
22,177
+1,862
| +9% | +$6.78K |
|
389
IDEAYA Biosciences
IDYA
$3.56B
| $88.7K | 0.03% |
4,220
-2,148
| -34% | -$41.2K |
|
390
Replimune Group
REPL
$1.01B
| $88.4K | 0.03% |
9,513
-3,921
| -29% | -$34.2K |
|
391
Denali Therapeutics
DNLI
$3.97B
| $88.1K | 0.03% |
6,300
-691
| -10% | -$9.73K |
|
392
Praxis Precision Medicines
PRAX
$10.1B
| $87.8K | 0.03% |
2,088
-228
| -10% | -$8.68K |
|
393
Structure Therapeutics
GPCR
$3.78B
| $87.8K | 0.03% |
4,232
-945
| -18% | -$20.8K |
|
|
BLTE
394
Belite Bio
BLTE
$6.54B
| $87.3K | 0.03% |
1,513
-1,076
| -42% | -$65.6K |
|
395
Viking Therapeutics
VKTX
$4B
| $87.2K | 0.03% |
3,290
-140
| -4% | -$3.69K |
|
396
Tyra Biosciences
TYRA
$1.58B
| $87.1K | 0.03% |
9,103
-1,715
| -16% | -$16.3K |
|
397
Kymera Therapeutics
KYMR
$8.94B
| $86.8K | 0.03% |
1,988
-1,903
| -49% | -$65.5K |
|
398
ArriVent BioPharma
AVBP
$1.44B
| $86.6K | 0.03% |
3,979
-2,369
| -37% | -$49.2K |
|
399
Monte Rosa Therapeutics
GLUE
$1.35B
| $86.2K | 0.03% |
19,112
-1,961
| -9% | -$8.75K |
|
400
Mineralys Therapeutics
MLYS
$2.41B
| $85.3K | 0.03% |
6,302
-7,192
| -53% | -$104K |
|
Similar funds
RC
MS
WI
HS
SIAG
WTFG
A6
ACM
Virtus Investment Advisers's Q2 2025 Portfolio in Review
As of Q2 2025, Virtus Investment Advisers held 509 positions worth $296M, down 20% from $368M the previous quarter. Its ten largest holdings account for 6.9% of the portfolio.
Virtus Investment Advisers withdrew a net $84.2M in Q2 2025, closing 70 positions and reducing 202 holdings. Its most notable exit was Virtus Newfleet ABS/MBS ETF, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 24% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Virtus Investment Advisers opened a new position in Constellation Energy worth $2.01M.
- Virtus Investment Advisers's largest Q2 2025 buy was Constellation Energy: 6,213 shares worth $2.01M.
- Virtus Investment Advisers added most to Amgen in Q2 2025, an estimated $1.45M increase.
- Virtus Investment Advisers's biggest Q2 2025 reduction was EOG Resources, cutting an estimated $1.23M.
- Virtus Investment Advisers fully exited Virtus Newfleet ABS/MBS ETF in Q2 2025, selling an estimated $32.2M.
- Virtus Investment Advisers's ten largest holdings make up 6.9% of its $296M portfolio in Q2 2025.
- Virtus Investment Advisers opened 39 new positions and closed 70 in Q2 2025.
- Virtus Investment Advisers's portfolio value fell 20% quarter-over-quarter to $296M.
Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.